Oncology Experts shared on LinkedIn:

“PF-07220060, another CDK4 inhibitor on the horizon.

Reported by Pfizer at AACR2024 as ‘the first-in-class CDK4 inhibitor’, this compound exhibited a broader therapeutic window (less neutropenia and superior antitumor efficacy), in mice and human, over the existing dual CDK4/6 inhibitors, Palbociclib, abemaciclib and ribociclib.

PF-07220060 shows robust tumor growth inhibition across CDK4-driven models of human breast and prostate cancer at clinically relevant doses.

This inhibitor has been advanced into Phase 3 trial in combination with Fulvestrant in advanced or metastatic HR-positive/HER2-negative breast cancer patients progressed on prior CDK4/6 inhibitor-based therapy.

Overall, the discovery of this inhibitor establishes proof-of-concept for CDK4 selective inhibition for treatment of HR+ HER2- breast cancer and other CDK4 dependent tumor types.

Previously, we shared with you another novel CDK4 inhibitor AU2-94, which shows better selectivity for CDK4 compared to PF-07220060.

Like this Pfizer’s compound, AU2-94 also demonstrated a highly promising preclinical safety and efficacy across multiple range of CDK4 dependent human malignancies, further corroborating the therapeutic advantage of selectively targeting CDK4 in cancer. .

Here is the link to the abstract!”

Source: Oncology Experts/LinkedIn